Literature DB >> 10998533

Nociceptin effects in the airways.

C Peiser1, B J Undem, A Fischer.   

Abstract

The opioid-like heptadecapeptide nociceptin (NC) has the following effects in the airways (investigated in isolated tracheae and bronchi from guinea pig or rat): the electric field stimulation (EFS)-induces release of acetylcholine (ACh), the tachykinin substance P (SP) and calcitonin gene-related peptide (CGRP) is reduced after pretreatment with NC, and EFS-induced tachykinergic nonadrenergic-noncholinergic (NANC) bronchoconstriction is inhibited by NC. Both the NC-mediated inhibition of neurotransmission and of smooth muscle contraction occurred in a concentration-dependent manner. Because these effects were naloxone-insensitive, were blocked by the NC receptor antagonist [F/G]NC(1-13)NH(2), and could be mimicked by the NC analogs, NCNH(2) and NC(1-13)NH(2), it is thought that they are distinct from the classic opioid receptors. That these pharmacological actions of NC are of relevance for airway physiology is highly probable given the presence of NC-immunoreactivity in the nerve fibers of the airways and of opioid-like receptor (ORL-1) transcripts in the jugular ganglia, from where the tachykinin-containing afferents arise.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10998533     DOI: 10.1016/s0196-9781(00)00239-4

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  2 in total

1.  Activation of the nociceptin/orphanin FQ receptor reduces bronchoconstriction and microvascular leakage in a rabbit model of gastroesophageal reflux.

Authors:  Bruno D'Agostino; Giuseppina Marrocco; Marilisa De Nardo; Girolamo Calò; Remo Guerrini; Luca Gallelli; Charles Advenier; Francesco Rossi
Journal:  Br J Pharmacol       Date:  2005-03       Impact factor: 8.739

2.  Nociceptin inhibits vanilloid TRPV-1-mediated neurosensitization induced by fenoterol in human isolated bronchi.

Authors:  Christophe Faisy; Emmanuel Naline; Céline Rouget; Paul-André Risse; Emmanuel Guerot; Jean-Yves Fagon; Thierry Chinet; Nicolas Roche; Charles Advenier
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-09-04       Impact factor: 3.000

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.